Although the standard procedures for detecting BRAF mutations are DNA-based, IHC has many advantages: IHC requires less tumor tissue, detects BRAFV600E mutations in specimens with low tumor content, and enables visualization of the location of mutated melanoma cells. Here, BRAF is linked to neoplasm.